Ellipse Technologies’ PRECICE® Limb Length Discrepancy Technology Used to Treat 2000th Patient
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Ellipse Technologies, Inc., a global medical device company, announced today that its PRECICE limb length discrepancy technology has now been used to treat 2000 patients since its debut on the market three years ago.
The FDA-cleared and CE-Marked technology offers a quality of life enhancing option that helps patients of all ages who have limb length discrepancies. The PRECICE system includes an intramedullary nail that can be post-operatively and non-invasively adjusted, with precision, via an External Remote Controller. This advancement enables distraction osteogenesis with improved precision and bi-directional control during the lengthening phase, as reported in multiple peer-reviewed medical journals.
Prior to the introduction of the PRECICE system, the most common method of treatment included an extended, painful process involving adjustable external fixation systems, which are attached to the bone through skin incisions. Postoperative pain with external fixation devices can be significant and affect the quality of life and functional mobility often requiring prolonged medication use. Surgeons have long sought alternative, less invasive ways with reduced complications to treat patients with limb length discrepancies.
“In light of this landmark 2000th patient announcement, we’re very proud that our PRECICE technology has been so well received by the clinician and patient communities,” said Ellipse’s President and CEO, Ed Roschak. “It’s particularly gratifying that this acceptance has been for a technology designed to provide substantial quality of life improvements for patients – which is our core mission at Ellipse. With the PRECICE system, we firmly believe that we are establishing a new standard of care to treat limb length discrepancy.”
Roschak added that in the last year alone, more than 100 new surgeons started utilizing the PRECICE technology.
